Drug intelligence / Profile preview

MVA-BN-HER2 + trastuzumab

Development stage: Unknown
Lead developer: Bavarian Nordic
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous, Subcutaneous (trastuzumab), Intramuscular (MVA-BN-HER2 - Vaccine Vector)

Overview

MVA-BN-HER2 + trastuzumab is a combination immunotherapeutic regimen for HER2-positive breast cancer, combining a recombinant cancer vaccine and a monoclonal antibody. **MVA-BN-HER2** is a Modified Vaccinia Ankara (MVA)-based vaccine encoding a modified human epidermal growth factor receptor 2 (HER2) antigen, designed to induce potent Th1-biased HER2-specific cellular and antibody immune responses, diminish immunosuppressive regulatory T cell activity, and drive infiltration of activated CD8+ cytotoxic T cells into tumor tissue[1][2]. **Trastuzumab** is a humanized monoclonal antibody that binds the extracellular domain of HER2 protein and blocks signaling, triggers immune-mediated cytotoxicity, and inhibits proliferation of HER2-overexpressing cancer cells[5]. This combination aims to synergize vaccine-induced immune activation with antibody-mediated direct targeting and immunologic killing of HER2-positive tumor cells in breast cancer[1][2][3][5].

Brand names: Herceptin (trastuzumab)Hercessi (trastuzumab)Herzuma (trastuzumab)Kanjinti (trastuzumab)Ogivri (trastuzumab)Ontruzant (trastuzumab)Trazimera (trastuzumab)
Other names: MVA-BN-HER2MVA-BN-HER-2MVA-BN-HER 2trastuzumabMVA-BN®-HER2

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on MVA-BN-HER2 + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVA-BN-HER2 + trastuzumab.

Explore the full profile